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Summary
Background: In the Netherlands in 1997, 43% of patients with newly diagnosed lung
cancer were over 70. Large age-speciﬁc differences in treatment exist. We examined
whether age, comorbidity, performance status and pulmonary function inﬂuenced
treatment.
Patients and methods: Data on patients with newly diagnosed non-small cell lung can-
cer (N = 803) were obtained: comorbidity, performance status, pulmonary function
(FEV1) and initial treatment. Age-speciﬁc differences in treatment according to the
guidelines were examined. Odds ratios were calculated by means of logistic regression
analyses.
Results: 82% with stage I or II disease received treatment according to the guidelines;
this applied to 48% with stage IIIA disease and to 54% with stage IIIB disease. For all
stages, this proportion decreased with increasing age. In stage IV disease, 36% did not
receive any treatment; this applied to 52% of the elderly patients (75+ years). Multi-
variate analyses showed associations between comorbidity and treatment choice, but
none with performance status. Age of 75+ years appeared to be the most important
factor for not receiving treatment according to guidelines.
*Corresponding author. Tel.: +31-43-3875463; fax: +31-43-3875457.
E-mail address: jdrj@sane.azm.nl (J.M. de Rijke).
0169-5002/$ – see front matter © 2004 Elsevier Ireland Ltd. All rights reserved.
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Conclusion: A substantial proportion of elderly patients with non-small cell lung
cancer did not receive standard treatment. Performance status and comorbidity
seldom formed the underlying reason. Calendar rather than biological age seemed
to play the most important role in choice of treatment for patients with non-small
cell lung cancer.
© 2004 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
Lung cancer is a major health problem in the
Netherlands, as it is in almost every Western coun-
try. Forty-three per cent of patients with newly
diagnosed lung cancer are older than 70 years [1].
A previous study showed that more elderly patients
with various forms of cancer often did not receive
any treatment or received less extensive treatment
than their younger counterparts [2].
Large age-speciﬁc differences in the diagnostic
procedure and treatment methods were especially
found in non-small cell lung cancer.
The presence of concurrent health conditions,
also known as comorbidities, is seen as one of the
most important reasons not to apply the standard
therapy. Without comorbidity adjustment, it can be
argued that any apparent age bias in decision mak-
ing is only a reﬂection of the poorer general health
of older patients. In earlier studies, effects were
found even after adjusting for comorbidity [3] or
performance status [4]. This strongly suggests that
physicians are basing their decisions on calendar
age rather than on biological age. Population-based
studies on age-speciﬁc treatment differences in
non-small cell lung cancer patients are scarce and
very few have addressed several important prog-
nostic factors, such as comorbidity, performance
status and pulmonary function in association with
the actual treatment received [5]. In the present
study, elaborate treatment data (e.g. dose of ra-
diation received) were retrieved from the medical
ﬁles. While taking into account the regional treat-
ment guidelines, we analysed the inﬂuence of age,
comorbidity, performance status and pulmonary
function on the choice of treatment for non-small
cell lung cancer patients.
2. Patients and methods
2.1. Study population
Data on patients with newly diagnosed non-small
cell lung cancer were provided by two regional can-
cer registries: the cancer registry department of
the Comprehensive Cancer Centre East (IKO) for the
period 1 January—1 June 1998 (N = 283) and the
Maastricht Cancer Registry, department of the Com-
prehensive Cancer Centre Limburg (IKL) for the pe-
riod 1 May 1997—1 May 1998 (N = 520). The total
area represented a population of around 2.1 mil-
lion in 1997. All cases not conﬁrmed to be small
cell tumours were considered as being non-small
cell lung cancer, including those without histolog-
ical/cytological conﬁrmation. This means that in
some cases the stage could not be deﬁned (stage
not applicable).
As this study addressed determinants of treat-
ment choice in a non-selected population, we also
included patients whose lung cancer was not their
ﬁrst primary malignancy (15% of the total study
group). Registration clerks actively collected data
on all the patients from the medical records. In
addition to the standard cancer registry items on
diagnosis, stage and initial treatment, extensive
treatment data were documented, such as the total
dose of radiotherapy received, comorbidity, per-
formance status and pulmonary function (forced
expiratory volume in 1 s (FEV1)).
Data on comorbidity and performance status
were extracted from previous hospital admissions,
letters of referral or discharge to general practi-
tioners, the medical history, current medication
and preoperative assessments. Comorbidity was
recorded using a slightly adapted list of serious dis-
eases developed by Charlson et al. (see Appendix
A) [6]. Having an earlier malignancy also forms part
of the Charlson comorbidity index.
Different rating systems are used in oncology to
assess performance status, i.e. a patient’s func-
tional capacity to work and perform daily activi-
ties: the Karnofsky scale [7], the scale described
by Zubrod et al. [8] which has been adapted by
the Eastern Oncology Group (ECOG) and the World
Health Organisation (WHO). The registration clerks
recorded all the rating systems used by the spe-
cialists; for the analyses, the different scales were
translated into the WHO scale (see Appendix B).
Although performance status is recognised as be-
ing an important prognostic factor in patients with
lung cancer [9] this item is not well-documented by
physicians. Therefore the registration clerks had to
estimate a patient’s performance status on the ba-
sis of medical history reports written in the medical
ﬁles by physicians and nurses.
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In lung cancer patients, pulmonary function as-
sessment forms part of the standard diagnostic pro-
cedure. To estimate the inﬂuence of this item, the
forced expiratory volume in 1 s (FEV1) and the dif-
fusion capacity for carbon monoxide (DLCO) were
recorded. In the analyses, only the FEV1 was used,
however, because DLCO was missing in the majority
(54%) of cases.
Clinical stage is recorded by the registries ac-
cording to the current TNM classiﬁcation system.
A new edition of the TNM classiﬁcation was pub-
lished in 1997 and became widely available in 1998
[10]. In the present study, however, the 1987 edition
[11] with adaptations from 1992 [12] was used, be-
cause the prevailing regional treatment guidelines
for non-small cell lung cancer, published in 1997
[13] were based on the 1992 TNM classiﬁcation. The
subsequent changes in the TNM classiﬁcation have
already been mentioned. The most important adap-
tation was that a T3 tumour without positive lymph
nodes (N0) was classiﬁed as stage IIIA, while in the
new version, this is stage IIB.
Patients staged as cMx were not considered to
have distant metastases (cM0), provided that T and
N were known.
Guidelines valid in the IKL region [13] dated back
to April 1997, while those in the IKO region were
from 1988 [14]. The guidelines in the two regions
were compatible, although those in the IKL region
weremore speciﬁc. The latter deﬁnitions were used
in our analyses, in order to make differences and
variations more visible and concrete.
On the basis of detailed information on the treat-
ment received in the ﬁrst 3 months after diagnosis,
we examined whether patients had been treated in
accordance with the guidelines (stages I + II, IIIA,
Table 1 Deﬁnitions of treatment according to the guidelines by stage
TNM stage Intention Treatment according to the guidelines
Stages I and II (T1—2 N0—1 M0) Curative Surgery, including local excision, lobectomy and
pneumectomy
Radiotherapy (RT) 60Gy (2Gy fractions) or 51Gy
(3Gy fractions)
Stage III A (T1—2 N2
M0, T3 N0—2 M0)
Long locoregional control Surgery ± RT
Radiotherapy 60Gy (2Gy fractions) or 55Gy
(2.5Gy fractions) ± chemotherapy
Stage IIIB (any T N3
M0; T4 any N M0)
Locoregional control Surgery ± RT
Radiotherapy 50Gy (2Gy fractions) or 40Gy (2.5
fractions) ± chemotherapy
Palliation Radiotherapy 40—49Gy (2Gy fractions) or
30—39Gy (3Gy fractions)
Stage IV (any T any N M1) Palliation Radiotherapy
IIIB). Treatment deﬁnitions per stage according to
the guidelines are given in Table 1. For stage IV, we
examined which patients received palliative treat-
ment and which patients did not.
2.2. Analyses
Adjusted and unadjusted odds ratios for whether
or not treatment had been received according to
the guidelines were calculated by means of logis-
tic regression analyses (SAS, procedure LOGIST).
As treatment guidelines are deﬁned by stage of
disease, subgroup analyses were performed for pa-
tients with stages I and II, stage IIIA and stage IIIB,
and stage IV. Variables included in themodels (back-
wards, α 0.05) were age (0—59 years (reference
category (ref)), 60—74 years, 75+ years), sex,
comorbidity (no concomitant disease (ref), 1—2
concomitant diseases, 3 or more concomitant dis-
eases), performance status (0 (ref), 1—2, 3—4, un-
known), FEV1 (<2.5 L(ref), >2.5 L, unknown) and
Cancer Registry (IKO/IKL). For stage IIIA, a variable
for T3N0 tumour (no positive lymph nodes) was
included (yes/no), because of the changes in TNM
versions.
Initially, ‘‘having an earliermalignancy’’ (yes/no),
was also included in the multivariate model. Be-
cause no independent inﬂuence on the outcome
variable (treated according to the guidelines
yes/no) was found this variable was not included in
the ﬁnal model which is presented in the results.
3. Results
The total study population comprised 803 patients
with non-small cell lung cancer. Eighty per cent of
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Table 2 Patient characteristics NSCLC (1997—1998) stratiﬁed by age group
Age (year)
≤59, N (%) 60—74, N (%) 75+, N (%) Total, N (%)
Sex
Women 69 (39) 73 (18) 23 (11) 165 (20)
Men 107 (61) 338 (82) 193 (89) 638 (80)
Stage
I 35 (20) 111 (27) 57 (26) 203 (25)
II 4 (2) 3 (1) 3 (1) 10 (1)
IIIA 32 (18) 67 (16) 31 (14) 130 (16)
IIIB 35 (20) 72 (18) 40 (19) 147 (18)
IV 61 (35) 113 (27) 50 (23) 224 (28)
X, NAa 9 (5) 45 (11) 35 (16) 89 (11)
Histology
Large cell carcinoma 48 (27) 77 (19) 35 (16) 160 (20)
Squamous cell carcinoma 51 (29) 168 (41) 100 (46) 319 (40)
Adenocarcinoma 62 (35) 110 (27) 36 (17) 208 (26)
Otherb 11 (6) 27 (7) 19 (9) 57 (7)
No histological veriﬁcation 4 (2) 29 (7) 26 (12) 59 (7)
Comorbidity (no)
0 106 (60) 99 (24) 43 (20) 248 (31)
1 38 (22) 152 (37) 73 (34) 263 (33)
2 16 (9) 86 (21) 48 (22) 150 (19)
≥3 4 (2) 54 (13) 42 (19) 100 (12)
Unknown 12 (7) 20 (5) 10 (5) 42 (5)
Performance status
0 99 (56) 181 (44) 79 (37) 359 (45)
1 20 (11) 80 (19) 53 (24) 153 (19)
2 14 (8) 30 (7) 19 (9) 63 (8)
3 5 (3) 13 (3) 6 (3) 24 (3)
4 2 (1) 5 (1) 3 (1) 10 (1)
Unknown 36 (20) 102 (25) 56 (26) 194 (24)
Region
IKL 112 (64) 267 (65) 141 (65) 520 (65)
IKO 64 (36) 144 (35) 75 (35) 283 (35)
Total 176 (100) 411 (100) 216 (100) 803 (100)
a X, unknown (N = 27); NA, not applicable ((N = 62) (no histology N = 59; tumour cells not otherwise speciﬁed
(NOS) N = 3)).
b Other: tumour cells NOS (N = 3); carcinoma NOS (N = 32); carcinoma undifferentiated NOS (N = 3); pseudosarco-
matous carcinoma (N = 1); carcinoid NOS (N = 6); neuroendocrine carcinoma (N = 6); adenosquamous carcinoma
(N = 6).
the patients were male and 20% were female; 51%
were aged between 60 and 74 years and 27% were
aged 75 years or older. Table 2 shows some relevant
patient characteristics stratiﬁed by age group. Pro-
portions of stage IV decreased with increasing age,
while proportions of stage unknown or not applica-
ble increased with increasing age.
The proportion of patients with one or more co-
morbidities increased with increasing age and the
proportion of patients with a good performance sta-
tus was lower among the elderly patients.
3.1. Stages I and II
In the patients with stage I or II disease, 82% re-
ceived treatment according to the guidelines, i.e.
surgery or radiotherapy (Tables 1 and 4). However,
the proportions decreased with increasing age,
from 97% in the age group 59 years and younger, to
86% in the age group 60—74 years and to 65% in the
age group 75 years and older.
Surgical procedures (N = 142) were lobectomy
(64%), pneumectomy (31%) and smaller resections
Treatm
ent
for
patients
w
ith
non-sm
allcelllung
cancer
237
Table 3 Adjusted and unadjusted Odds Ratios (OR) with 95% conﬁdence interval in parentheses for treatment of NSCLC not according to the guidelines (stages
I and II, IIIA, IIIB) and for no treatment (stage IV)
Stages I and II Stage IIIA Stage IIIB Stage IV
Unadjusted OR Adjusted OR Unadjusted OR Adjusted OR Unadjusted OR Adjusted OR Unadjusted OR Adjusted OR
Age (year)
≤59 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref)
60—74 3.2 (0.9—11) 2.2 (0.6—8.1) 1.3 (0.6—3.0) 1.2 (0.4—3.4) 1.1 (0.5—2.5) 0.8 (0.3—2.1) 2.1 (1.0—4.4) 2.1 (0.9—5.0)
75+ years 12.8 (3.5—46) 8.5 (2.2—32) 3.6 (1.2—10) 3.9 (1.1—14) 3.5 (1.3—9.1) 2.2 (0.7—6.8) 4.7 (2.0—11) 5.1 (2.0—13)
Pulmonary function (FEV1)
< 2.5 L 1.5 (0.7—3.1) 1.0 (0.5—2.3) 1.1 (0.5—2.3) 0.9 (0.3—2.6) 2.8 (1.1—7.1) 2.3 (0.8—6.2) 4.2 (1.4—13) 3.9 (1.2—12)
≥ 2.5 L 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Unknown 2.4 (0.9—6.8) 2.4 (0.7—8.3) 2.2 (0.7—6.8) 2.5 (0.6—10) 3.0 (1.1—8.2) 1.9 (0.6—5.8) 4.6 (1.5—14) 4.7 (1.4—15)
Comorbidity
0 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref)
1—2 6.5 (2.2—19) 4.8 (1.5—15) 1.0 (0.5—2.3) 1.3 (0.5—3.2) 2.3 (1.1—4.8) 1.9 (0.8—4.4) 1.2 (0.6—2.2) 0.8 (0.4—1.7)
3≥ 8.2 (2.4—28) 5.7 (1.5—21) 0.9 (0.3—2.5) 0.7 (0.2—2.2) 1.9 (0.7—5.1) 1.3 (0.4—4.0) 1.2 (0.5—3.0) 0.7 (0.3—1.8)
Performance status
0 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref)
1—2 3.1 (1.4—6.8) 2.1 (0.9—4.9) 1.5 (0.6—3.3) 1.8 (0.7—4.6) 1.7 (0.8—3.7) 1.5 (0.7—3.4) 1.1 (0.5—2.1) 0.9 (0.4—1.8)
3—4 — — 6.3 (0.7—57) 2.9 (0.3—30) 5.2 (0.5—52) 5.3 (0.4—64) 1.1 (0.3—3.4) 0.9 (0.2—3.3)
Unknown 1.2 (0.5—2.6) 0.8 (0.3—1.9) 1.6 (0.6—4.3) 1.5 (0.5—4.9) 2.1 (0.9—5.1) 2.1 (0.8—5.7) 1.4 (0.7—3.0) 1.3 (0.6—2.8)
TNM T3N0
Yes Not Applicable 0.1 (0.0—0.4) 0.08 (0.0—0.3) Not applicable Not applicable
No 1 (ref) 1 (ref)
Comprehensive Cancer Centre
IKO 1 (ref) 1 (ref) 1 (ref) 1 (ref)
IKL 1.1 (0.5—2.0) a 0.7 (0.3—1.4) a 0.9 (0.4—1.9) a 1.1 (0.6—1.9) a
a Variable not included in the ﬁnal model.
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(5%) (data not shown). In this group, 95% of the
patients without any serious concomitant diseases
and 73% of the patients with three or more con-
comitant diseases were treated according to the
guidelines. More patients with a good performance
status (WHO grade 0) received treatment accord-
ing to the guidelines then patients with a poorer
performance status (WHO grade 1—2). In a logis-
tic regression model, the factor age of 75 years
or older was associated with higher proportions of
patients who did not receive treatment according
to the guidelines (OR = 8.5; 95% CI 2.2—32). Also
the presence of comorbidity appeared to signiﬁ-
cantly inﬂuence the treatment of this group of lung
cancer patients (Table 3). After adjusting for the
other variables, ORs for performance status were
no longer signiﬁcantly increased.
3.2. Stage III A
About 48% of the patients with stage IIIA NSCLC re-
ceived treatment according to the guidelines, i.e.
surgery with or without radiotherapy, radiother-
apy alone or in combination with chemotherapy
(Table 1 and 4). More patients aged 75 years and
older had not been treated according to the guide-
lines (71%) than their younger counterparts. In the
univariate as well as the multivariate analyses, age
was the most important risk factor for not receiving
treatment according to the guidelines (Table 3).
The presence of one or more comorbidities, or
other variables such as performance status and
pulmonary function did not show any signiﬁcant
association with not receiving treatment accord-
ing to the guidelines. In patients without positive
lymph nodes (T3N0) the risk of not being treated
according to the guidelines was signiﬁcantly lower
than in the other categories of stage IIIA (OR 0.08,
95% CI: 0.03—0.33).
3.3. Stage IIIB
Fifty-four per cent of the patients with stage IIIB
disease received treatment according to the guide-
lines, i.e. surgery, radiotherapy, a combination of
the two, or RT with chemotherapy (Table 1). In
patients aged 75 years and over, this proportion
was lower: 33% (Table 4). The large majority (73%)
of stage IIIB patients who were treated according
to the guidelines received radiotherapy alone; 29
out of these 58 patients received a palliative dose
(not shown). In the univariate analysis, age of 75
years and over, pulmonary function (FEV1 < 2.5 L
or unknown) and the presence of one or two co-
morbidities showed a signiﬁcantly higher risk for
not receiving treatment according to the guidelines
(Table 3). However, in the multivariate analyses,
none of these factors remained signiﬁcantly associ-
ated with the risk of not being treated according to
the guidelines.
3.4. Stage I + II, IIIA, IIIB, treatment not
according to the guidelines
Table 5 shows the patients with stage I + II, IIIA
and IIIB who had not been treated according to the
guidelines: 37 patients with stages I and II NSCLC
had not been treated according to the guidelines
and 24 had not received any treatment, all of
them were 60 years or older. Radiotherapy with
less than a total dose of 60Gy (2Gy fractions) or
51Gy (2.5Gy fractions) had been received by 11
patients, whereas one patient had received RT in
combination with chemotherapy and one patient
had been treated with chemotherapy alone.
Fifty-one per cent of the stage IIIA patients did
not receive treatment according to the guidelines.
In this group, 28 patients had received radiother-
apy alone, but a total dose of less than 60Gy (2Gy
fractions) or 55Gy (2.5Gy fractions); 17 patients
received chemotherapy with or without another
modality, but not according to the guidelines, while
21 patients (16%) did not receive any treatment.
In contrast with stage IIIA, a large proportion of
the stage IIIB patients were not treated at all
(66%) and this percentage increased with increas-
ing age. Treatment consisted of radiotherapy with
a dose of less than 30Gy (19%) or chemotherapy
(13%).
3.5. Stage IV
In the years 1997 and 1998 there was no clear stan-
dard treatment for stage IV NSCLC. Survival rates
were low and treatment was administered for pal-
liative purposes. Table 6 shows the proportions of
patients who received treatment and those who
did not. No treatment had been applied to 36%
(N = 76) of the patients. This proportion differed
by age group: 20% of the patients aged 59 years or
younger had not been treated, 34% of the patients
aged 60—74 years and 52% of those aged 75 years
or older. Patients who had been treated mostly
received radiotherapy (N = 94) or chemotherapy
(N = 30) (Table 6). Table 7 presents treatment by
age and whether radiotherapy was locoregional,
to metastases, or both. The proportion of pa-
tients that received radiotherapy to metastases
decreased with increasing age: 43% of the patients
aged 59 years or younger, 26% of the patients aged
60—74 years and 18% of the patients aged 75 years
and over. Chemotherapy was mostly administered
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Table 4 Patient characteristics stages I and II, IIIA, IIIB NSCLC and distribution of treatment (not) according to the guidelines
Stages I and II Stage IIIA Stage IIIB
Not according to
guidelines N (%)
According to
guidelines N (%)
Total N Not according to
guidelines N (%)
According to
guidelines N (%)
Total N Not according to
guidelines N (%)
According to
guidelines N (%)
Total N
Age (year)
≤59 1 (3) 38 (97) 39 13 (41) 19 (59) 32 13 (37) 22 (63) 35
60—74 15 (13) 98 (86) 114a 31 (46) 35 (52) 67a 28 (39) 44 (61) 72
75+ 21 (35) 39 (65) 60 22 (71) 9 (29) 31 27 (67) 13 (33) 40
Pulmonary function (FEV1)
0.5—1.0 L 3 (25) 9 (75) 12 5 (83) 1 (17) 6 4 (50) 4 (50) 8
1.1—2.4 L 19 (17) 91 (83) 110 30 (45) 36 (55) 66 33 (51) 32 (49) 65
≥2.5 L 7 (10) 60 (90) 67 17 (47) 19 (53) 36 8 (27) 22 (73) 30
Unknown 8 (35) 15 (65) 23 14 (64) 7 (32) 22a 23 (52) 21 (48) 44
Therapy
No therapy 24 (100) — 24 21 (100) — 21 45 (100) — 45
Surgery — 123 (100) 123 — 16 (100) 16 — 8 (100) 8
Radiotherapy (RT) 11 (25) 33 (75) 44 28 (49) 29 (51) 57 13 (18) 58 (82) 71
Surgery + RT — 19 (100) 19 — 8 (100) 8 — 4 (100) 4
Chemotherapy (CT) 1 (50) — 2a 9 (100) — 9 9 (100) — 9
RT + CT 1 (100) — 2 (17) 10 (83) 12 — 9 (100) 9
S + CT/S + RT + CT — — 6 (100) — 6 1 (100) — 1
Comorbidity (number)
0 2 (3) 54 (95) 57a 21 (51) 20 (49) 41 18 (34) 35 (66) 53
1 13 (18) 60 (82) 73 25 (54) 21 (46) 46 26 (59) 18 (41) 44
2 11 (23) 36 (77) 47 6 (43) 8 (57) 14 12 (46) 14 (54) 26
≥3 8 (27) 22 (73) 30 10 (50) 9 (45) 20a 8 (42) 11 (58) 19
Unknown 3 (50) 3 (50) 6 4 (44) 5 (56) 9 4 (80) 1 (20) 5
Performance status
0 16 (12) 110 (87) 127a 27 (45) 34 (55) 62a 22 (37) 38 (63) 60
1 5 (16) 26 (84) 31 16 (50) 16 (50) 32 20 (56) 16 (44) 36
2 3 (60) 2 (40) 5 5 (71) 2 (29) 7 6 (37) 10 (63) 16
3—4 — — — 5 (83) 1 (17) 6 3 (75) 1 (25) 4
Unknown 13 (26) 37 (74) 50 13 (56) 10 (44) 23 17 (55) 14 (45) 31
Comprehensive Cancer Centre
IKL 24 (16) 124 (83) 149a 41 (54) 34 (45) 76a 42 (47) 48 (53) 90
IKO 13 (20) 51 (80) 64 25 (46) 29 (54) 54 26 (46) 31 (54) 57
Total 37 (17) 175 (82) 213 (100) 66 (51) 63 (48) 130 (100) 68 (46) 79 (54) 147
a Treatment of one patient was unknown.
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Table 5 Patients with NSCLC not treated according to the guidelines (stages I and II, IIIA, IIIB)
Age (year)
≤59, N (%) 60—74, N (%) 75+, N (%) Total, N (%)
Stages I and II
No therapy — 9 (60) 15 (71) 24 (65)
RT < 60Gy (2Gy fractions) or <
51Gy (3Gy fractions)
1 (100) 4 (27) 6 (29) 11 (30)
CT/RT + CT — 2 (13) — 2 (5)
Subtotal 1 (100) 15 (100) 21 (100) 37 (100)
Stage III A
No therapy 4 (31) 5 (16) 12 (55) 21 (16)
RT < 60Gy (2Gy fractions) or
<55Gy (2.5Gy fractions)
2 (15) 17 (55) 9 (41) 28 (42)
Chemotherapy (CT) 2 (15) 6 (19) 1 (4) 9 (14)
Surgery (S) + CT 2 (15) 2 (6) — 4 (6)
Radiotherapy (RT) + CT 2 (15) — — 2 (3)
S + RT + CT 1 (8) 1 (3) — 2 (3)
Subtotal 13 (100) 31 (100) 22 (100) 66 (100)
Stage IIIB
No therapy 6 (46) 16 (57) 23 (85) 45 (66)
Radiotherapy < 30Gy 1 (8) 9 (32) 3 (11) 13 (19)
Chemotherapy 6 (46) 2 (7) 1 (4) 9 (13)
S + RT + CT — 1 (4) — 1 (2)
Subtotal 13 (100) 28 (100) 27 (100) 68 (100)
to younger patients and consisted of regimens with
gemcitabine.
Logistic regression analysis for whether or not
treatment had been received revealed that an age
of 75 years or older and an FEV1 of lower than 2.5 L
or FEV1 unknown was related to not receiving treat-
ment.
3.6. Stage unknown/not applicable
Twenty-seven patients had stage unknown because
of an incomplete diagnostic procedure and in 62
patients there was no histological classiﬁcation,
which means that their stage could not be deﬁned.
In this group, 80 out of the 89 patients were aged
60 years and older. The majority (54%) had not
received treatment and this proportion increased
with increasing age: 33% of the patients aged 59
years and younger, 49% of the patients aged 60—74
years and 66% of those aged 75 years and over. In
the total group who received treatment (N = 41),
15% underwent surgery and 25% received radio-
therapy (results not shown).
Logistic regression analyses (results not shown)
indicated that the factors age 75 years or older (OR
2.9; 95% CI:1.3—6.6), performance status of WHO
3-4 (OR 2.4; 95% CI:1.0—6.0) or unknown pulmonary
function (OR 3.4; 95% CI:1.5—7.3) were associated
with stage unknown or the absence of histological
classiﬁcation.
4. Discussion
The present retrospective study investigated treat-
ment patterns for non-small cell lung cancer pa-
tients in the eastern and southern part of the
Netherlands. Less than half the patients with a
stage I, II, IIIA or IIIB disease (44%) were treated
according to the guidelines. Adherence to treat-
ment guidelines was highest in stages I and II and
decreased with increasing age. The majority of
patients with stage IV disease received palliative
treatment (63%), but the proportions varied by age
group: 79% in the age group 59 years and younger,
64% in the age group 60—74 years and 44% in the
age group 75 years and over.
After adjustment for the effect of age and cancer
stage, the inﬂuences of comorbidity and perfor-
mance status on treatment choice were less than
expected. In the univariate analyses, signiﬁcant as-
sociations with comorbidity and performance sta-
tus were only found for the localised stages. Poor
pulmonary function (FEV1) was associated with not
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Table 6 Patient characteristics stage IV NSCLC, treatment or no treatment
Stage IV
No treatment Treatment Treatment unknown Total
Age
≤59 years 12 (20) 48 (79) 1 (2) 61
60—74 years 38 (34) 72 (64) 3 (3) 113
75+ years 26 (52) 22 (44) 2 (4) 50
Pulmonary function (FEV1)
0.5—1.0 L 3 (43) 4 (57) — 7
1.1—2.4 L 32 (36) 54 (61) 3 (3) 89
≥2.5 L 4 (12) 28 (85) 1 (3) 33
Unknown 37 (39) 56 (59) 2 (2) 95
Therapy
No therapy 76 (100) — — 76
Surgery — 4 (100) — 4
Radiotherapy (RT) — 94 (100) — 94
Surgery + RT — 3 (100) — 3
Chemotherapy (CT) — 30 (100) — 30
RT + CT — 11 (100) — 11
Unknown — — 6 (100) 6
Comorbidity (no)
0 25 (32) 53 (67) 1 (1) 76
1 26 (37) 44 (63) — 70
2 14 (33) 26 (62) 2 (5) 42
3≥ 6 (33) 11 (61) 1 (6) 18
Unknown 5 (33) 8 (53) 2 (14) 15
Performance status
0 26 (32) 55 (68) — 82
1 12 (29) 29 (71) — 40
2 11 (41) 16 (59) — 27
3—4 5 (33) 10 (67) — 15
Unknown 22 (37) 32 (53) 6 (10) 59
Comprehensive Cancer Centre
IKL 47 (33) 90 (64) 4 (3) 141
IKO 29 (35) 52 (63) 2 (2) 83
Total 76 (34) 142 (63) 6 (3) 224 (100)
receiving palliative treatment in stage IV patients,
even after adjustment for age, comorbidity and
performance status.
Several factors should be considered when in-
terpreting these ﬁndings. First, comorbidity data,
performance status and pulmonary function (FEV1)
were not part of the standard registration items
at the time of data collection (comorbidity was
included in 1999). This means that registration
clerks were not used to documenting these items.
To record comorbidity, methods introduced by the
adjacent cancer registry in Eindhoven (IKZ) were
used. They have been recording comorbidity since
1993 and a validation project has been carried
out [3]. To evaluate the data on comorbidity in
the present study, the prevalence of comorbidity
in lung cancer patients was compared to the out-
comes of the IKZ study [3]. Differences were in a
range of 1—6% for both men and women in seven
out of eight categories.
Second, even though great effort was made,
information on performance status and FEV1 was
difﬁcult to obtain from the medical ﬁles. In 14%
of the cases it was clear that no FEV1 test had
been performed, while in 12% of the cases the
notes in the medical ﬁles were not clear about the
performance of pulmonary function tests. In both
categories, the performance status was coded as
unknown (percentage by age group: ≤59 years:
20%, 60—74 years: 25% and 75+ years: 26%).
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Table 7 Treatment for stage IV NSCLC by age
Treatment Age (Year)
≤59, N (%) 60—74, N (%) 75+, N (%) Total, N (%)
No treatment 12 (20) 38 (34) 26 (52) 76 (34)
Surgery 1 (2) 3 (3) — 4 (2)
Radiotherapy (RT)
locoregional 6 (10)a 12 (11) 4 (8) 22 (10)
Radiotherapy metastases 26 (43)b 30 (26) 9 (18) 65 (29)
Radiotherapy both 4 (6)c 10 (9) 4 (8) 18 (8)
Chemotherapy 11 (18) 15 (13) 4 (8) 30 (13)
Unknown 1 (1) 5 (4)d 3 (6) 9 (4)
Total 61 (27) 113 (50) 50 (22) 224 (100)
a One patient received RT + chemotherapy.
b One patient received Surgery + RT and ﬁve patients received RT + chemotherapy.
c One patient received S + RT.
d Two patients received RT but the localisation and dose was unknown.
Comorbidity signiﬁcantly inﬂuenced treatment
choice for the early stage non-small cell lung can-
cer. This might be related to the fact that the
prevalence of comorbidity in patients with a stages
I and II NSCLC was higher than that in patients
with more advanced lung cancer (Table 2). This
phenomenon was also found by Janssen-Heijnen
et al. [3], who ascribed it to screening bias, e.g.
lung cancer was diagnosed at an early stage as a
result of regular monitoring of other chronic dis-
eases. This might also explain the high proportion
of elderly patients with stages I and II at diagnosis,
although this could be partly the result of under-
staging due to less extensive diagnostic procedures
[2]. A higher proportion of elderly patients with
stages I and II was also found earlier [15,16] but
not conﬁrmed by others [17].
In the present study, stage was classiﬁed accord-
ing to the ‘old’ TNM classiﬁcation [12]. In the new
TNM classiﬁcation [10], cases with T3N0 (no posi-
tive lymph nodes) are classiﬁed as IIB instead of IIIA.
This change in TNM classiﬁcation was made because
apparently, these patients have better survival and
should be offered treatment with curative intent.
In the present study, T3N0 patients were anal-
ysed in more detail, because physicians may have
been aware of the more favourable prognosis and
have treated them according to the new staging
classiﬁcation [18]. Compared to the other stage
IIIA patients, more T3N0 patients had been treated
according to the guidelines. A fairly large propor-
tion of the other stage IIIA patients had received
radiotherapy to a lower total dose than advised
in the guidelines (N = 28), or they had received
no treatment at all (N = 21); the majority of the
latter patients were aged 60 years and older.
There are no curative treatment options for pa-
tients with metastasised lung cancer (stage IV).
Radiotherapy administered for palliation of severe
respiratory symptoms or for metastases causing
severe complaints was a generally accepted treat-
ment policy. Therefore the characteristics of the
patients who received such treatment (to prolong
survival or for symptomatic relief) were compared
to those of the patients who did not receive any
treatment. This comparison revealed different pro-
portions by age group: 44% of the patients aged
75 years and over received some kind of pallia-
tive treatment, mostly radiotherapy, whereas this
was 64% in the age group 60—74 years and 79%
in patients aged 59 years and younger. Relatively
fewer elderly patients received radiotherapy for
metastases.
Clinicians who managed elderly patients with
lung cancer may have felt cautious about refer-
ring them for radiotherapy. In the study period
1997—1998, research speciﬁcally performed to as-
sess the problems and beneﬁts of radiotherapy for
lung cancer in elderly patients was scarce [19].
Patterson et al. retrospectively studied 149 lung
cancer patients aged 75 years and over. They con-
cluded that palliative radiotherapy was well toler-
ated and the response was similar to that in younger
patients. Other studies have also indicated that
(radical) radiotherapy can be applied to elderly
people without increased toxicity [20—23]. How-
ever, heterogeneity among individuals increases
with increasing age, and more than in younger
cancer patients, all therapeutic options should be
considered in relation with careful evaluation of
the patient (functional assessment, comorbidities,
stage of disease, social situation, individual wishes
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for therapy, etc.) [24—26]. Another positive de-
velopment over the past few years is that most
clinical trials no longer specify upper age limits.
Unfortunately the recruitment of elderly patients
in trials is still low [27].
Especially in the younger age groups with ad-
vanced stage NSCLC, chemotherapy seemed to oc-
cupy a fairly important position in the treatment
options; 30 patients received chemotherapy alone
and 11 received both radiotherapy and chemother-
apy. At time of the study, 1997—98, the role of
chemotherapy in stage IV NSCLC in everyday prac-
tice was still uncertain and did not form part of
the IKL or IKO treatment guidelines. However, in
1995, the results of a meta-analysis on randomised
trials revealed an increase in median survival of
about 6 weeks and a 10% improvement in 1-year
survival compared to patients managed with sup-
portive care only [28]. In subsequent years it has
become clear that several chemotherapy regimens
could offer a small increase in 1-year survival and
a delay in symptoms that cause quality of life de-
terioration in elderly and unﬁt patients [29]. These
developments led to changes in the IKL treatment
guideline [30] by making chemotherapy part of the
standard treatment, although it is still advised to
do this in trial settings.
In the present study, performance status did not
seem to play a major role in treatment choice,
which is in agreement with Brown et al. [4] who
studied differences in treatment for 563 lung cancer
patients in the UK. We found that performance sta-
tus as such was often not even mentioned in medi-
cal ﬁles. Besides, the percentage of patients with a
very poor performance status (3—4), was low. Only
4% had a performance status of 3—4 (proportions
were higher in patients with stage IV (7%) and stage
unknown (10%)).
Our study population included 89 patients with
unknown stage, partly because of less extensive
diagnostic procedures (N = 27) and partly because
the diagnosis was not histologically conﬁrmed
(N = 62). The high prevalence of comorbidities
and the poor performance status of these patients
may indicate that the diagnostic procedure was
less extensive because of comorbid conditions or
low performance status which implicitly meant
that patients were not considered to be candi-
dates for standard treatment. In some cases, this
may have been the result of the misunderstanding
that extensive clinical staging in the elderly is not
worthwhile [31]. It seems likely that from the very
beginning of the diagnostic process, there was no
intention to treat these patients according to the
guidelines. Obviously, there will sometimes be very
good reasons not to perform extensive diagnostic
procedures, or not to treat a patient according to
the standard guidelines (e.g. lower RT dose). From
the documentation of the reasons for treatment
choice, it was learned that occasionally the dis-
ease was progressing too rapidly or sometimes the
treatment-related complications were considered
unacceptable. Nevertheless, in the literature there
are strong indications that a nihilist approach from
physicians plays an important role [32] and that
the number of patients who refuse treatment is
very small [33].
In the present study, the calendar age of the pa-
tient was the most important factor upon which
physicians based their therapy decision. Fairly large
proportions of elderly patients were not treated,
were undertreated or were withheld some form of
treatment for palliation. Exclusion of elderly pa-
tients from former cancer trials and lack of data
concerning the beneﬁt of treatment for elderly pa-
tients with cancer may have played a role in treat-
ment decisions.
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Appendix A. Classiﬁcation of
co-morbidity, according to an adapted
version of the list developed by Charlson
et al. [6]
COPD
Cardiovascular disease (myocardial infarction,
cardiac decompensation, angina pectoris, inter-
mittent claudication, abdominal aneurysm)
Cerebrovascular diseases (cerebrovascular acci-
dent, hemiplegia)
Othermalignancies (except for basal cell skin car-
cinoma)
Hypertension
Diabetes Mellitus (medically treated)
Other
Soft tissue diseases (Besnier Boeck disease (sar-
coidosis), Wegener’s granulomatosis, systemic lu-
pus erythematosis (SLE)
Rheumatoid arthritis (only severe)
Kidney diseases (chronic glomerulonephritis,
chronic pyelonephritis)
Bowel diseases (Crohn’s disease, ulcerative coli-
tis)
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Liver diseases (cirrhosis, hepatitis)
Dementia
Tuberculosis
Appendix B
WHO (Zubrod) scale
0 Normal activity
1 Symptoms, but nearly fully ambulatory
2 Some bed rest, but needs to be
in bed for less than 50% of
normal daytime
3 Needs to be in bed for more
than 50% of normal daytime
4 Unable to get out of bed
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